United Capital Financial Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

United Capital Financial Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-42,995	Closed	-$860	–	1139
2025 Q1	$860	Hold	42,995	–	–	﹤0.01%	1063
2024 Q4	$6.88K	Hold	42,995	–	–	﹤0.01%	1059
2024 Q3	$9.89K	Buy	+42,995	New	+$15.8K	﹤0.01%	1053

United Capital Financial Advisors's VIRX Position: Q2 2025 in Review

United Capital Financial Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2025, closing a stake of 42,995 shares — an estimated $860 sold.

United Capital Financial Advisors first reported a position in VIRX in Q3 2024 and held it in 3 quarters. The position peaked at $9.89K in Q3 2024. 0 funds tracked by Wall St. Rank hold VIRX as of Q2 2025.

United Capital Financial Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
United Capital Financial Advisors sold 42,995 Viracta Therapeutics, Inc. Common Stock shares in Q2 2025, an estimated $860.
United Capital Financial Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2024 and held it in 3 quarters.
United Capital Financial Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $9.89K in Q3 2024.
0 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2025.

Based on United Capital Financial Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.